Medikinabio and the Korea Artificial Intelligence Association signed a strategic business agreement (MOU) for the convergence of artificial intelligence (AI) technology and the biomedical industry at the IR Room of Hall A, COEX, Seoul on the 14th. This agreement contains the purpose of both organizations applying AI technology to the biomedical field to realize precision medicine and advanced digital healthcare, and to secure future growth engines for the country through convergence between industries.
The existing clinical-centered bio industry is accelerating its convergence with AI technology due to the recent increase in demand for precision data-based research and development. This agreement is drawing attention because AI can play a key role in improving diagnostic accuracy, increasing the efficiency of new drug development, and analyzing medical information. The two organizations plan to promote joint research and verification of AI-based bio-medical technology, joint planning and execution of national projects, exchange of professional personnel and joint education, and hosting of technology seminars and forums.
Medikina Bio has discovered the liver cancer early diagnosis biomarker 'SORD' in collaboration with Seoul Asan Medical Center, Korea Pasteur Institute, etc., and is currently developing a miniaturized and automated field diagnostic device based on this with the Electronics and Telecommunications Research Institute, with the aim of commercializing it. Medikina Bio plans to increase diagnostic accuracy and prediction efficiency by incorporating AI technology, and to accelerate its entry into the global market.
In the digital healthcare field, various application technologies are expected to be developed, such as lifelog-based health management and personalized predictive medicine through data analysis. If the AI ecosystem network owned by the association and Medikinabio’s platform technology are combined, there is a high possibility that it will lead to innovation across the entire industry. In addition, the two organizations plan to operate joint programs for training practical talent and discovering and fostering startups.
Kim Hyun-chul, chairman of the Korea Artificial Intelligence Association, said, “When AI technology is combined with the medical and bio industries, it will play a key role in driving the nation’s future industries,” and “The association will actively cooperate to expand the industrial ecosystem and advance technology.” Choi Woo-sung, CEO of Medikinabio, said, “Based on biomarkers discovered through seven years of national research, we have developed an efficient liver cancer diagnostic kit and automated on-site screening equipment,” and “By incorporating AI technology, we will realize the intelligence of diagnostic devices and strengthen our global competitiveness.”
- See more related articles
You must be logged in to post a comment.